Researcher, National Polytechnic Institute, Mexico.
Jesús Alonso Gándara Mireles is an exemplary candidate for the Research for Young Scientist Award, with extensive qualifications in biotechnology. He holds a Bachelor’s degree and multiple master’s degrees, culminating in a PhD focused on pharmacokinetics and pharmacogenetics in oncology. Currently completing a Postdoctoral Fellowship at the National Polytechnic Institute, Jesús conducts research aimed at optimizing chemotherapy for pediatric cancer patients. His experience includes prestigious internships at the University at Buffalo and the University of San Diego, enhancing his expertise. As a member of key professional organizations, he demonstrates a strong commitment to advancing personalized medicine and improving patient outcomes.
Publication Profile :
Scopus
Educational Background :
Jesús’s educational achievements are impressive and relevant to his research interests. He holds a Bachelor’s degree in Biotechnology with a biomedical focus, followed by a Master’s in Molecular and Cellular Biology, a Master’s in Human Genetics, and a Master’s in Clinical Pharmacokinetics. His PhD, centered on pharmacokinetics and pharmacogenetics in oncology, underscores his specialized knowledge in this vital area of research. This rigorous academic training has equipped him with the necessary skills to tackle complex scientific problems in the field of cancer treatment.
Professional Experiences :
Jesús Alonso Gándara Mireles has accumulated extensive professional experience in biotechnology and clinical research, particularly in the fields of pharmacogenetics and pharmacokinetics. Currently, he is completing a Postdoctoral Fellowship at the National Polytechnic Institute (IPN), focusing on the pharmacokinetics of oncology agents in pediatric patients. His previous internships include significant roles in Clinical Pharmacokinetics at the National Institute of Pediatrics and Pediatric Cancer Pharmacology at the University at Buffalo. He also engaged in research on Pediatric Cancer Genetics at the University of San Diego. His work aims to optimize treatment strategies and reduce chemotherapy-induced adverse effects in childhood cancer.
Research Contribution :
Throughout his career, Jesús has gained valuable research experience through multiple internships. His exposure to pharmacokinetics and pharmacogenetics at prestigious institutions, including the University at Buffalo and the University of San Diego, highlights his capability to engage with leading experts and contribute to groundbreaking research. His current work focuses on optimizing chemotherapy for children by reducing adverse effects through personalized medicine, emphasizing his innovative approach to healthcare challenges.
Awards And Achievements :
Jesús Alonso Gándara Mireles has earned notable recogn ition throughout his academic and research career. As a member of the National System of Researchers (CONACYT) at Level 1, he has demonstrated his commitment to advancing scientific knowledge. His research contributions have been acknowledged through prestigious internships, including those at the National Institute of Pediatrics and the University at Buffalo. Additionally, Jesús is an active member of the International Society of Pediatric Oncology (SIOP) and the Latin American Society of Pharmacogenomics and Personalized Medicine (SOLFAGEM). These affiliations reflect his dedication to pediatric oncology and personalized medicine, underscoring his impactful contributions to the field.
Conclusion :
Jesús Alonso Gándara Mireles is an outstanding candidate for the Research for Young Scientist Award. His impressive educational background, significant research experience, and active participation in professional networks make him a valuable contributor to the field of biotechnology and pediatric oncology. His work has the potential to greatly improve treatment outcomes for children with cancer, demonstrating his commitment to advancing scientific knowledge and enhancing patient care. Therefore, I strongly endorse his nomination for this esteemed award.
Publication Top Notes :
- “Influence of Age, Gender and Body Mass Index on Intravenous Pharmacokinetics of Buprenorphine in Children Undergoing Orthopedic Surgery” (2024) – 🏥
- “Population pharmacokinetics and pharmacodynamics of L-asparaginase and its impact on the development of pancreatitis and hypersensitivity reactions in children with leukemia under treatment” (2024) – 🧬
- “Nutritional Status as a Risk Factor for Doxorubicin Cardiotoxicity in Mexican Children with Acute Lymphoblastic Leukemia” (2024) – 🍽️
- “Impact of single-nucleotide variants and nutritional status on population pharmacokinetics of Doxorubicin, and its effect on cardiotoxicity in children with leukemia” (2023) – ⚗️ Cited by: 3
- “Association of genetic polymorphisms NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 with the cardiotoxic effects of doxorubicin in children with acute lymphoblastic leukemia” (2021) – 🧬 Cited by: 8
- “Genotype Analysis of ABCC1, NCF4 and CBR3 Polymorphism and the Association With Childhood Acute Lymphoblastic Leukemia in Mexican Childhood Population” (2021) – 🔬 Cited by: 3